Corvus Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRVS and other ETFs, options, and stocks.

About CRVS

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. 

CEO
Richard A. Miller
CEORichard A. Miller
Employees
37
Employees37
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2014
Founded2014
Employees
37
Employees37

CRVS Key Statistics

Market cap
1.21B
Market cap1.21B
Price-Earnings ratio
-23.20
Price-Earnings ratio-23.20
Dividend yield
Dividend yield
Average volume
873.04K
Average volume873.04K
High today
$15.39
High today$15.39
Low today
$14.14
Low today$14.14
Open price
$15.12
Open price$15.12
Volume
776.10K
Volume776.10K
52 Week high
$26.95
52 Week high$26.95
52 Week low
$5.03
52 Week low$5.03

Stock Snapshot

Corvus Pharmaceuticals(CRVS) stock is priced at $14.33, giving the company a market capitalization of 1.21B. It carries a P/E multiple of -23.20.

On 2026-08-21, Corvus Pharmaceuticals(CRVS) stock moved within a range of $14.14 to $15.39. With shares now at $14.33, the stock is trading +1.3% above its intraday low and -6.9% below the session's peak.

Trading activity shows a volume of 776.1K, compared to an average daily volume of 873.04K.

Over the past 52 weeks, Corvus Pharmaceuticals(CRVS) stock has traded between a high of $26.95 and a low of $5.03.

Over the past 52 weeks, Corvus Pharmaceuticals(CRVS) stock has traded between a high of $26.95 and a low of $5.03.

CRVS News

Simply Wall St 20h
Will Corvus’ Sharply Wider 2026 Losses Recast Its Risk‑Reward Profile for Investors?

In August 2026, Corvus Pharmaceuticals, Inc. reported second-quarter 2026 results showing a net loss of US$17.96 million, or US$0.19 per basic and diluted share...

Will Corvus’ Sharply Wider 2026 Losses Recast Its Risk‑Reward Profile for Investors?
The Motley Fool 7d
Corvus Pharmaceuticals Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer-Richard A. Miller Chief Financial Officer-Leiv...

Corvus Pharmaceuticals Q2 2026 Earnings Call Transcript

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CRVS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.